<DOC>
	<DOCNO>NCT02255175</DOCNO>
	<brief_summary>Using neuroimaging , investigator study effect estrogen mood brain function perimenopausal woman either without depression .</brief_summary>
	<brief_title>Perimenopausal Effects Estradiol Reward Responsiveness</brief_title>
	<detailed_description>Despite decade research , affective disorder prevalent associate significant morbidity mortality . Unraveling pathophysiology affective disorder uniquely challenge depressive syndrome heterogeneous diverse etiology . Thus , past study aim identify neural genetic biomarkers would improve prediction susceptibility , course illness , treatment response yield inconsistent result . The investigator propose address problem study perimenopausal major depressive disorder ( MDD ) , depression subtype specific endocrine trigger ( i.e. , ovarian hormone withdrawal ) . Evidence support ovarian hormone withdrawal trigger affective dysfunction perimenopausal MDD include following : perimenopausal woman show temporal association ovarian hormone withdrawal onset mood symptom ; treatment estrogen reduces mood symptom ; blind estradiol withdrawal re-precipitates depression woman history perimenopausal MDD ( manuscript preparation ) . Focusing perimenopausal MDD , homogeneous subtype specific endocrine trigger , increase likelihood identify meaningful neurobiological markers.One powerful tool understand neural mediator MDD brain imaging . Prior research suggest frontostriatal reward system regulate estradiol implicate MDD . However , neural mechanism perimenopausal MDD never study . We assess neural reward system perimenopausal woman without MDD use functional magnetic resonance imaging ( fMRI ) baseline follow estradiol treatment . The central hypothesis neural reward system hypoactive perimenopausal MDD , antidepressant effect three-week transdermal estradiol intervention mediate increased activity neural reward system , assess use fMRI . The investigator test hypothesis execute follow aim : Aim 1 : To measure frontostriatal response reward perimenopausal MDD test effect estradiol neural activation perimenopausal woman . The investigator use fMRI baseline follow estradiol treatment woman without MDD probe frontostriatal reward circuitry . Aim 2 : To quantify motivated behavior baseline follow estradiol administration perimenopausal woman without MDD . Motivated behavior operationally define response latency reward versus non-reward fMRI reward task . Aim 3 : To measure psychological correlate frontostriatal response reward woman perimenopausal MDD baseline follow estradiol administration . Depressive symptom assess baseline follow estradiol administration . The result provide critical information neuroendocrine pathophysiology perimenopausal depression may subsequently contribute development novel pharmacologic intervention .</detailed_description>
	<mesh_term>Depression</mesh_term>
	<mesh_term>Depressive Disorder</mesh_term>
	<mesh_term>Estradiol</mesh_term>
	<mesh_term>Polyestradiol phosphate</mesh_term>
	<mesh_term>Estrogens</mesh_term>
	<mesh_term>Progesterone</mesh_term>
	<mesh_term>Estradiol 3-benzoate</mesh_term>
	<mesh_term>Estradiol 17 beta-cypionate</mesh_term>
	<mesh_term>Estradiol valerate</mesh_term>
	<criteria>1 . Perimenopause Status : We employ Stages Reproductive Aging Workshop ( STRAW ) criteria70 confirm perimenopausal status . The stage primarily base characteristic menstrual cycle secondarily follicle stimulate hormone ( FSH ) level . The anchor stag system final menstrual period ( FMP ) . We enroll woman ≥ 2 skip cycle interval amenorrhea ≥ 60 day , consistent late menopause transition ( stage 1 ) , demonstrate FSH level &gt; 25 IU/mL . Because extreme body weight ( BMI &lt; 18 &gt; 30 kg/m2 ) history chronic menstrual cycle irregularity contribute inaccurate reproductive staging , serve additional exclusion criterion ; 2 . MDD Group Eligibility Criterion : current diagnosis MDD onset associate menstrual cycle irregularity , history psychiatric illness 2 year onset current depressive episode determine Structure Clinical Interview DSMIVTR ( Diagnostic Statistical Manual4Text Revision ) Axis I Disorders ( SCID ) ; 3 . Control Group Eligibility Criterion : absence past present psychiatric disorder assess SCID . Patients permit enter protocol follow : 1. current medication use ( i.e. , psychotropics , antihypertensive , statin , hormonal preparation , frequent use antiinflammatory agent ( &gt; 10 times/month ) ) . Women allow enroll take medication without know mood effect ( e.g . stable thyroid hormone replacement occasional ( &lt; 5 times/month ) use Ambien ) * ; 2. pregnant , breastfeed try conceive ; 3 . FMP 12 month prior enrollment ; 4. history undiagnosed vaginal bleeding ; 5. undiagnosed enlargement ovary ; 6. polycystic ovary syndrome ; 7. history breast ovarian cancer ; 8. first degree relative ovarian cancer ; 9. first degree relative premenopausal onset bilateral breast cancer ; 10 . 2+ first degree relative breast cancer ( regardless onset ) ; 11 . 3+ relative postmenopausal breast cancer ; 12. abnormal find provider breast exam and/or mammogram ; 13. know carrier BRCA1 2 mutation ; 14. endometriosis ; 15. blood clot legs lung ; 16. porphyria ; 17. diabetes mellitus ; 18. malignant melanoma ; 19 . Hodgkin 's disease ; 20. recurrent migraine headache precede aura ; 21. gallbladder pancreatic disease** ; 22. heart kidney disease** ; 23. liver disease ; 24. cerebrovascular disease ( stroke ) ; 25. first degree relative history heart attack stroke ; 26. current cigarette smoking ; 27. current suicidal ideation psychosis ; 28. past suicide attempt psychotic episode require hospitalization ; 29. chronic depression ( i.e. , episode ( ) last 3+ year ) ; 30. recurrent depression ( i.e. , 1 prior episode , include episode postpartum onset ) 31. depressive episode ( ) within 2 year enrollment ; 32. selfreported claustrophobia 33. peanut allergy report prescription medication review clear study physician prior participant 's enrollment ; **participants give opportunity describe condition online screen survey . Reported condition acute nature and/or benign review study physician exclusion decide casebycase . All chronic condition exclusionary .</criteria>
	<gender>Female</gender>
	<minimum_age>44 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>Reproductive Affective Disorder</keyword>
	<keyword>Depression</keyword>
	<keyword>Perimenopause</keyword>
	<keyword>Estrogen</keyword>
	<keyword>Estradiol treatment</keyword>
	<keyword>Mood Disorders</keyword>
	<keyword>Estrogen Replacement Therapy</keyword>
	<keyword>Sex Steroids</keyword>
	<keyword>Depressive disorder</keyword>
	<keyword>Mental Disorders</keyword>
	<keyword>Estradiol</keyword>
	<keyword>Hormones</keyword>
	<keyword>Physiological effect drug</keyword>
	<keyword>Reproductive Control Agents</keyword>
</DOC>